Full Text View
Tabular View
No Study Results Posted
Related Studies
ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
This study has been terminated.
( Futility )
Study NCT00300196   Information provided by Neurobiological Technologies

First Received on March 6, 2006.   Last Updated on January 11, 2010   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Stroke
Cerebral Ischemia
Brain Infarction
Additional conditions recognized in this trial
Brain Ischemia
Cerebral Infarction
Infarction
Ischemia
More general conditions related to this trial
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Necrosis
Nervous System Diseases
Pathologic Processes
Vascular Diseases
Interventions listed in this trial
Ancrod (Viprinex)
Placebo
Additional drug interventions recognized in this trial
Ancrod
More general drug interventions related to this trial
Anticoagulants
Cardiovascular Agents
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Neurobiological Technologies


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services